Works matching DE "FLUDARABINE"

Results: 1105

Remission of lymphoma and rheumatoid arthritis following anti-CD19 chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma.

Published in:

2025

By:

Masihuddin, Aliya;
Liebowitz, Jason;
Reshef, Ran;
Bathon, Joan

Publication type:

Case Study

Alemtuzumab May Lead to Longer Overall Survival in CLL Patients With Poor Prognostic Factors.

Published in:: Oncology (08909091), 2008, v. 22, n. 14, p. 1632
Publication type:: Article

FCR vs FC Improves Response Rates and Progression-Free Survival of Previously Untreated Patients With Advanced Chronic Lymphocytic Leukemia.

Published in:: Oncology (08909091), 2008, v. 22, n. 14, p. 1604
Publication type:: Article

Rituximab, Fludarabine, and Cyclophosphamide Prolongs Progression-Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Published in:: Oncology (08909091), 2008, v. 22, n. 14, p. 1578
Publication type:: Article

New Therapeutic Options for Chronic Lymphocytic Leukemia.

Published in:

Oncology (08909091), 2007, v. 21, n. 14, p. 1649

By:

Boyiadzis, Michael;
Pavletic, Steven;
Foon, Kenneth A.

Publication type:

Article

What Is the Optimal Initial Treatment for Chronic Lymphocytic Leukemia?

Published in:

Oncology (08909091), 2007, v. 21, n. 14, p. 1641

By:

Lin, Thomas S.

Publication type:

Article

Teucrium polium induces apoptosis in peripheral blood lymphocytes isolated from human chronic lymphocytic leukemia.

Published in:

Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journal of Serbia, 2020, v. 77, n. 12, p. 1252, doi. 10.2298/VSP181010005Z

By:

Zarić, Milan;
Zarić, Radica Živković;
Mitrović, Marina;
Nikolić, Ivana;
Čanović, Petar;
Milosavljević, Zoran;
Jovanović, Danijela;
Zelen, Ivanka

Publication type:

Article

Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine.

Published in:

European Journal of Health Economics, 2002, v. 3, n. 3, p. 166, doi. 10.1007/s10198-002-0112-y

By:

Herold, M.;
Hieke, K.

Publication type:

Article

Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.

Published in:

International Journal of Clinical Oncology, 2009, v. 14, n. 3, p. 197, doi. 10.1007/s10147-008-0826-7

By:

Imataki, Osamu;
Ohnishi, Hiroaki;
Ohbayashi, Yumiko;
Kitanaka, Akira;
Kubota, Yoshitsugu;
Ishida, Toshihiko;
Tanaka, Terukazu

Publication type:

Article

The impact of age and renal function on the pharmacokinetics and protein binding characteristics of fludarabine in paediatric and adult patients undergoing allogeneic haematopoietic stem cell transplantation conditioning.

Published in:

European Journal of Clinical Pharmacology, 2024, v. 80, n. 12, p. 1967, doi. 10.1007/s00228-024-03751-0

By:

Nath, Christa E.;
Rosser, Sebastian P. A.;
Nath, Kiran K.;
Chung, Jason;
Larsen, Stephen;
Gibson, John;
Gabriel, Melissa;
Shaw, Peter J.;
Keogh, Steven J.

Publication type:

Article

Predicting the presence and mechanism of busulfan drug-drug interactions in hematopoietic stem cell transplantation using pharmacokinetic interaction network–based molecular structure similarity and network pharmacology.

Published in:

European Journal of Clinical Pharmacology, 2021, v. 77, n. 4, p. 595, doi. 10.1007/s00228-020-03034-4

By:

Hao, Chenxia;
Ma, Xiaoqin;
Wang, Lining;
Zhang, Weixia;
Hu, Jiong;
Huang, Jingjing;
Yang, Wanhua

Publication type:

Article

The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia.

Published in:

European Journal of Clinical Pharmacology, 2015, v. 71, n. 9, p. 1121, doi. 10.1007/s00228-015-1893-0

By:

Podhorecka, Monika;
Klimek, Piotr;
Chocholska, Sylwia;
Szymczyk, Agnieszka;
Macheta, Arkadiusz;
Kowal, Malgorzata;
Dmoszynska, Anna;
Hus, Marek

Publication type:

Article

Obecabtagene Autoleucel for B-Cell Acute Lymphoblastic Leukemia.

Published in:

JAMA Network Open, 2025, v. 8, n. 4, p. 1354, doi. 10.1001/jama.2024.28312

By:

Bouchkouj, Najat;
Przepiorka, Donna;
Fashoyin-Aje, Lola A.

Publication type:

Article

Kronik Lenfositik Losemili Hastalarda T Lenfosit Alt Gruplarının Değerlendirilmesi.

Published in:

Turkish Journal of Immunology, 2020, v. 8, n. 1, p. 6, doi. 10.25002/tji.2020.1240

By:

Gelmez, Metin Yusuf;
Çınar, Suzan;
Dağlar-Aday, Aynur;
Özçit-Gürel, Gülce;
Yönal-Hindilerden, İpek;
Deniz, Günnur;
Aktan, Melih

Publication type:

Article

STAT6 phosphorylation upregulates microRNA-155 expression and subsequently enhances the pathogenesis of chronic lymphocytic leukemia.

Published in:

Oncology Letters, 2019, v. 18, n. 1, p. 95, doi. 10.3892/ol.2019.10294

By:

Chen, Na;
Feng, Lili;
Lu, Kang;
Li, Peipei;
Lv, Xiao;
Wang, Xin

Publication type:

Article

BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients.

Published in:

Oncology Letters, 2016, v. 11, n. 5, p. 3240, doi. 10.3892/ol.2016.4388

By:

ALHOURANI, EYAD;
OTHMAN, MONEEB A. K.;
MELO, JOANA B.;
CARREIRA, ISABEL M.;
GRYGALEWICZ, BEATA;
VUJIĆ, DRAGANA;
ZECEVIĆ, ZELJKO;
JOKSIĆ, GORDANA;
GLASER, ANITA;
POHLE, BEATE;
SCHLIE, CORDULA;
HAUKE, SVEN;
LIEHR, THOMAS

Publication type:

Article

Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine.

Published in:

Molecular & Clinical Oncology, 2017, v. 7, n. 4, p. 525, doi. 10.3892/mco.2017.1364

By:

CHEN CHEN;
HONGMIN HE

Publication type:

Article

Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients.

Published in:

Molecular & Clinical Oncology, 2016, v. 4, n. 4, p. 667, doi. 10.3892/mco.2016.765

By:

ZHIMING DAI;
JIE LIU;
WANG-GANG ZHANG;
XINGMEI CAO;
YANG ZHANG;
ZHIJUN DAI

Publication type:

Article

Successful desensitization protocol for a patient with fludarabine anaphylaxis during hematopoietic transplantation.

Published in:

Pediatric Allergy & Immunology, 2022, v. 33, n. 6, p. 1, doi. 10.1111/pai.13789

By:

Xu, Mei;
AlRiyami, Layla;
Rao, Harini;
Hook, Roxanne;
Wall, Donna A.;
Schechter, Tal;
Grunebaum, Eyal

Publication type:

Article

The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.

Published in:

Frontiers in Immunology, 2019, p. 1, doi. 10.3389/fimmu.2019.02455

By:

Lorenzo-Herrero, Seila;
Sordo-Bahamonde, Christian;
Bretones, Gabriel;
Payer, Ángel R.;
González-Rodríguez, Ana P.;
González-García, Esther;
Pérez-Escuredo, Jhudit;
Villa-Álvarez, Mónica;
Núñez, Luz-Elena;
Morís, Francisco;
Gonzalez, Segundo;
López-Soto, Alejandro

Publication type:

Article

Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation.

Published in:

Bone Marrow Transplantation, 2015, v. 50, n. 10, p. 1371, doi. 10.1038/bmt.2015.144

By:

Barba, P;
Martino, R;
Orti, G;
Esquirol, A;
Perez-Hoyos, S;
Sierra, J;
Valcárcel, D

Publication type:

Article

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.

Published in:

Bone Marrow Transplantation, 2015, v. 50, n. 7, p. 939, doi. 10.1038/bmt.2015.58

By:

Konopleva, M;
Benton, C B;
Thall, P F;
Zeng, Z;
Shpall, E;
Ciurea, S;
Kebriaei, P;
Alousi, A;
Popat, U;
Anderlini, P;
Nieto, Y;
Parmar, S;
Qiao, W;
Chen, J;
Rondon, G;
McMullin, B;
Wang, R-Y;
Lu, H;
Schober, W;
Woodworth, G

Publication type:

Article

Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.

Published in:

Bone Marrow Transplantation, 2015, v. 50, p. S37, doi. 10.1038/bmt.2015.93

By:

Bacigalupo, A;
Dominietto, A;
Ghiso, A;
Di Grazia, C;
Lamparelli, T;
Gualandi, F;
Bregante, S;
Van Lint, M T;
Geroldi, S;
Luchetti, S;
Grasso, R;
Pozzi, S;
Colombo, N;
Tedone, E;
Varaldo, R;
Raiola, A M

Publication type:

Article

Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update.

Published in:

Bone Marrow Transplantation, 2015, v. 50, p. S24, doi. 10.1038/bmt.2015.91

By:

Arcese, W;
Picardi, A;
Santarone, S;
De Angelis, G;
Cerretti, R;
Cudillo, L;
Pennese, E;
Bavaro, P;
Olioso, P;
Dentamaro, T;
Cupelli, L;
Chierichini, A;
Ferrari, A;
Mengarelli, A;
Tirindelli, M C;
Testi, M;
Di Piazza, F;
Di Bartolomeo, P

Publication type:

Article

Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders.

Published in:

Bone Marrow Transplantation, 2015, v. 50, n. 3, p. 367, doi. 10.1038/bmt.2014.269

By:

Hong, S;
Le-Rademacher, J;
Artz, A;
McCarthy, P L;
Logan, B R;
Pasquini, M C

Publication type:

Article

Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.

Published in:

Bone Marrow Transplantation, 2015, v. 50, n. 2, p. 248, doi. 10.1038/bmt.2014.250

By:

Tang, B L;
Zhu, X Y;
Zheng, C C;
Liu, H L;
Geng, L Q;
Wang, X B;
Ding, K Y;
Yao, W;
Tong, J;
Song, K D;
Zhang, L;
Qiang, P;
Sun, Z M

Publication type:

Article

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 9, p. 1162, doi. 10.1038/bmt.2014.131

By:

Shanavas, M;
Messner, H A;
Atenafu, E G;
Kim, D H;
Kuruvilla, J;
Lipton, J H;
Uhm, J;
Seftel, M;
Alam, N;
Gupta, V

Publication type:

Article

Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 9, p. 1170, doi. 10.1038/bmt.2014.133

By:

Kharfan-Dabaja, M A;
Labopin, M;
Bazarbachi, A;
Hamladji, R M;
Blaise, D;
Socié, G;
Lioure, B;
Bermudez, A;
Lopez-Corral, L;
Or, R;
Arcese, W;
Fegueux, N;
Nagler, A;
Mohty, M

Publication type:

Article

A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 7, p. 955, doi. 10.1038/bmt.2014.66

By:

Gotoh, M;
Yoshizawa, S;
Katagiri, S;
Suguro, T;
Asano, M;
Kitahara, T;
Akahane, D;
Okabe, S;
Tauchi, T;
Ito, Y;
Ohyashiki, K

Publication type:

Article

Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 7, p. 913, doi. 10.1038/bmt.2014.84

By:

Bhatia, M;
Jin, Z;
Baker, C;
Geyer, M B;
Radhakrishnan, K;
Morris, E;
Satwani, P;
George, D;
Garvin, J;
Del Toro, G;
Zuckerman, W;
Lee, M T;
Licursi, M;
Hawks, R;
Smilow, E;
Baxter-Lowe, L A;
Schwartz, J;
Cairo, M S

Publication type:

Article

Outcomes following second allogeneic haematopoietic transplants using fludarabine-melphalan conditioning.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 6, p. 852, doi. 10.1038/bmt.2014.23

By:

Bilmon, I;
Nivison-Smith, I;
Hertzberg, M;
Ritchie, D;
Greenwood, M;
Spencer, A;
Kennedy, G;
Bryant, A;
Moore, J

Publication type:

Article

Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 5, p. 622, doi. 10.1038/bmt.2014.15

By:

Dirou, S;
Malard, F;
Chambellan, A;
Chevallier, P;
Germaud, P;
Guillaume, T;
Delaunay, J;
Moreau, P;
Delasalle, B;
Lemarchand, P;
Mohty, M

Publication type:

Article

Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 4, p. 485, doi. 10.1038/bmt.2013.214

By:

Magni, M;
Nicola, M Di;
Patti, C;
Scimè, R;
Mulè, A;
Rambaldi, A;
Intermesoli, T;
Viero, P;
Tarella, C;
Gueli, A;
Bergui, L;
Trentin, L;
Barzan, A;
Benedetti, F;
Ambrosetti, A;
Di Raimondo, F;
Chiarenza, A;
Parvis, G;
Billio, A;
Attolico, I

Publication type:

Article

Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 4, p. 513, doi. 10.1038/bmt.2013.221

By:

Wondergem, M J;
Dijkstra, F S;
Visser, O J;
Zweegman, S;
Ossenkoppele, G J;
Witte, B I;
Janssen, J J W M

Publication type:

Article

Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 4, p. 519, doi. 10.1038/bmt.2013.224

By:

Gao, L;
Li, Y;
Zhang, Y;
Chen, X;
Zhang, C;
Liu, Y;
Kong, P;
Wang, Q;
Su, Y;
Wang, C;
Wang, S;
Li, B;
Sun, A;
Du, X;
Zeng, D;
Li, J;
Liu, H;
Zhang, X

Publication type:

Article

Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 4, p. 589, doi. 10.1038/bmt.2013.234

By:

Griffiths, C D;
Ng, E S M;
Kangarloo, S B;
Williamson, T S;
Chaudhry, M A;
Booker, R;
Duggan, P;
Yue, P;
Savoie, L;
Brown, C;
Cox-Kennett, N;
Russell, J A;
Daly, A;
Storek, J

Publication type:

Article

Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 2, p. 248, doi. 10.1038/bmt.2013.167

By:

Chen, G L;
Zhang, Y;
Hahn, T;
Abrams, S;
Ross, M;
Liu, H;
McCarthy, P L

Publication type:

Article

Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 1, p. 11, doi. 10.1038/bmt.2013.121

By:

Kunter, G;
Perkins, J B;
Pidala, J;
Nishihori, T;
Kharfan-Dabaja, M A;
Field, T;
Fernandez, H;
Perez, L;
Locke, F;
Ayala, E;
Tomblyn, M;
Ochoa-Bayona, J L;
Betts, B;
Nieder, M;
Anasetti, C

Publication type:

Article

Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.

Published in:

Bone Marrow Transplantation, 2014, v. 49, n. 1, p. 17, doi. 10.1038/bmt.2013.142

By:

Bryant, A;
Nivison-Smith, I;
Pillai, E S;
Kennedy, G;
Kalff, A;
Ritchie, D;
George, B;
Hertzberg, M;
Patil, S;
Spencer, A;
Fay, K;
Cannell, P;
Berkahn, L;
Doocey, R;
Spearing, R;
Moore, J

Publication type:

Article

Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation.

Published in:

Bone Marrow Transplantation, 2013, v. 48, n. 10, p. 1317, doi. 10.1038/bmt.2013.116

By:

Nakasone, H;
Onizuka, M;
Suzuki, N;
Fujii, N;
Taniguchi, S;
Kakihana, K;
Ogawa, H;
Miyamura, K;
Eto, T;
Sakamaki, H;
Yabe, H;
Morishima, Y;
Kato, K;
Suzuki, R;
Fukuda, T

Publication type:

Article

Salvage allogeneic hematopoietic SCT for primary graft failure in children.

Published in:

Bone Marrow Transplantation, 2013, v. 48, n. 9, p. 1173, doi. 10.1038/bmt.2013.36

By:

Kato, M;
Matsumoto, K;
Suzuki, R;
Yabe, H;
Inoue, M;
Kigasawa, H;
Inagaki, J;
Koh, K;
Hashii, Y;
Tauchi, H;
Suminoe, A;
Kikuta, A;
Sakamaki, H;
Kawa, K;
Kato, K;
Fukuda, T

Publication type:

Article

Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.

Published in:

Bone Marrow Transplantation, 2013, v. 48, n. 9, p. 1179, doi. 10.1038/bmt.2013.37

By:

Nishihori, T;
Ochoa-Bayona, J L;
Kim, J;
Pidala, J;
Shain, K;
Baz, R;
Sullivan, D;
Jim, H S;
Anasetti, C;
Alsina, M

Publication type:

Article

Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.

Published in:

Bone Marrow Transplantation, 2013, v. 48, n. 7, p. 982, doi. 10.1038/bmt.2012.261

By:

Medd, P G;
Peniket, A J;
Littlewood, T J;
Pearce, R;
Perry, J;
Kirkland, K E;
Shaw, B E;
Potter, M N;
Craddock, C F;
Milligan, D W;
Fielding, A K;
Marks, D I;
Cook, G

Publication type:

Article

Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation.

Published in:

Bone Marrow Transplantation, 2013, v. 48, n. 8, p. 1098, doi. 10.1038/bmt.2013.3

By:

Duque-Afonso, J;
Ihorst, G;
Wäsch, R;
Bertz, H;
Müller-Quernheim, J;
Finke, J;
Prasse, A;
Marks, R

Publication type:

Article

Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.

Published in:

Bone Marrow Transplantation, 2013, v. 48, n. 7, p. 901, doi. 10.1038/bmt.2012.267

By:

Christopoulos, P;
Schmoor, C;
Waterhouse, M;
Marks, R;
Wäsch, R;
Bertz, H;
Finke, J

Publication type:

Article

Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.

Published in:

Bone Marrow Transplantation, 2013, v. 48, n. 5, p. 708, doi. 10.1038/bmt.2012.211

By:

DeCook, L J;
Thoma, M;
Huneke, T;
Johnson, N D;
Wiegand, R A;
Patnaik, M M;
Litzow, M R;
Hogan, W J;
Porrata, L F;
Holtan, S G

Publication type:

Article

Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.

Published in:

Bone Marrow Transplantation, 2013, v. 48, n. 5, p. 646, doi. 10.1038/bmt.2012.218

By:

Parker, T L;
Cooper, D L;
Seropian, S E;
Bolognia, J L

Publication type:

Article

Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation.

Published in:

Bone Marrow Transplantation, 2013, v. 48, n. 5, p. 729, doi. 10.1038/bmt.2012.196

By:

Helton, K J;
Patay, Z;
Triplett, B M

Publication type:

Article

Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning.

Published in:

Bone Marrow Transplantation, 2013, v. 48, n. 2, p. 196, doi. 10.1038/bmt.2012.251

By:

Maury, S;
Aljurf, M

Publication type:

Article

Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.

Published in:

Bone Marrow Transplantation, 2012, v. 47, n. 10, p. 1287, doi. 10.1038/bmt.2012.13

By:

Sanz, J;
Boluda, J C H;
Martín, C;
González, M;
Ferrá, C;
Serrano, D;
de Heredia, C D;
Barrenetxea, C;
Martinez, A M;
Solano, C;
Sanz, M A;
Sanz, G F

Publication type:

Article